NASDAQ$NBIX
Neurocrine Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022 and reiterated financial guidance for 2022.
Neurocrine Biosciences reported first quarter net product sales of $303 million for INGREZZA. The company's GAAP net income was $14 million, or $0.14 per share, and non-GAAP net income was $30 million, or $0.30 per share.
- INGREZZA's first quarter net product sales were $303 million with total prescriptions (TRx) of approximately 57,600.
- Net product sales and TRx grew 32% and 33%, respectively, vs. first quarter of 2021.
- The company completed its salesforce expansion in April, establishing separate psychiatry, neurology, and long-term care teams.
- Mitsubishi Tanabe Pharma Corporation (MTPC) received Japanese Ministry of Health, Labour and Welfare approval for DYSVAL® (valbenazine) for the treatment of tardive dyskinesia in Japan.
Headline financials
Revenue & EPS history
Neurocrine Biosciences · Revenue · Quarterly
$311M
Revenue by segment
Neurocrine Biosciences · $303M total across 1 segment · Q1 2022
- INGREZZA Net Product Sales$303M+31.7%100.0%
Forward guidance
The company reiterated its 2022 financial guidance for INGREZZA net product sales of $1.25 - $1.35 billion, GAAP R&D expense of $380 - $415 million, Non-GAAP R&D expense of $325 - $360 million, GAAP SG&A expense of $720 - $735 million, and Non-GAAP SG&A expense of $605 - $620 million.
Tailwinds
- INGREZZA sales guidance for fiscal 2022 reflects approximately 20% year-over-year growth, at the mid-point of the range.
- Sales guidance is based on recent trends.
- Sales guidance is based on an anticipated improving COVID-19 related environment throughout the year.
- Sales guidance is based on benefit from the company's recently completed salesforce expansion during the second half of 2022.
- The company plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the second half of 2022.
Headwinds
- If new COVID-19 related disruptions emerge, the Company’s ability to meet these expectations could be negatively impacted.
- GAAP R&D guidance includes amounts for milestones that are probable of achievement or have been achieved.
- GAAP R&D Guidance includes approximately $7 million of milestone expense for the Xenon collaboration which was achieved in January 2022.
- Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of $60 million in R&D.
- Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of $110 million in SG&A.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+1.6%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+17.2%
Q3 2017
Best reaction
-18.5%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | +11.5% | +21.3% | |
| Q4 2025 | -10.4% | -7.0% | -5.6% | |
| Q3 2025 | -6.3% | -3.7% | +3.2% | |
| Q1 2025 | +8.3% | +5.4% | +13.5% | |
| Q4 2024 | -18.5% | -22.1% | -24.9% | |
| Q3 2024 | +3.5% | +3.7% | +9.1% | |
| Q2 2024 | +8.2% | +2.9% | -10.2% | |
| Q1 2024 | +1.7% | +3.0% | -1.5% | |
| Q4 2023 | -6.0% | -8.8% | -2.6% | |
| Q3 2023 | +4.1% | +5.0% | +8.8% | |
| Q2 2023 | +2.2% | -0.3% | +6.9% | |
| Q1 2023 | -7.4% | -5.4% | -10.8% | |
| Q4 2022 | -5.6% | -6.2% | -11.1% | |
| Q3 2022 | +6.0% | +5.8% | +9.7% | |
| Q2 2022 | +10.6% | +14.5% | +9.5% | |
| Q1 2022 | -3.9% | -14.6% | +7.7% | |
| Q4 2021 | +8.7% | +7.9% | +12.2% | |
| Q3 2021 | -9.3% | -11.6% | -23.4% | |
| Q2 2021 | -2.8% | -6.6% | +0.4% | |
| Q1 2021 | -2.3% | -0.3% | +3.2% | |
| Q4 2020 | +3.1% | +2.6% | -17.3% | |
| Q3 2020 | -9.1% | -4.5% | -4.5% | |
| Q2 2020 | -0.2% | -4.4% | -3.7% | |
| Q1 2020 | +7.0% | +11.6% | +13.8% | |
| Q4 2019 | +2.0% | +3.5% | -5.4% | |
| Q3 2019 | -1.2% | +6.9% | +14.4% | |
| Q2 2019 | +9.7% | +7.5% | +11.3% | |
| Q1 2019 | -6.7% | +2.0% | +1.4% | |
| Q4 2018 | -4.6% | -4.6% | -12.9% | |
| Q3 2018 | -8.0% | -9.0% | -25.5% | |
| Q2 2018 | +14.7% | +17.2% | +23.3% | |
| Q1 2018 | +3.3% | +1.5% | +17.1% | |
| Q4 2017 | +3.9% | +3.7% | +11.6% | |
| Q3 2017 | +17.2% | +20.0% | +18.5% | |
| Q2 2017 | +10.2% | +10.5% | +17.4% | |
| Q1 2017 | +3.4% | +3.8% | -15.3% | |
| Q4 2016 | +0.7% | +4.5% | +7.2% | |
| Q3 2016 | -10.0% | -1.1% | -3.1% | |
| Q2 2016 | -0.7% | -3.6% | -2.0% | |
| Q1 2016 | -0.1% | — | — | |
| Q4 2015 | +6.9% | — | — | |
| Q3 2015 | -4.5% | — | — | |
| Q2 2015 | -3.7% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +5.7% | — | — | |
| Q3 2014 | -4.9% | — | — | |
| Q2 2014 | -2.3% | — | — | |
| Q1 2014 | -3.5% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -6.3% | — | — | |
| Q2 2013 | +0.5% | — | — | |
| Q1 2013 | +2.3% | — | — | |
| Q4 2012 | +6.5% | — | — | |
| Q3 2012 | -1.7% | — | — | |
| Q2 2012 | -9.6% | — | — | |
| Q1 2011 | -3.2% | — | — | |
| Q1 2012 | -3.2% | — | — | |
| Q4 2011 | -8.0% | — | — | |
| Q4 2009 | -8.0% | — | — | |
| Q3 2010 | +13.7% | — | — | |
| Q3 2011 | +13.7% | — | — | |
| Q4 2010 | -6.5% | — | — | |
| Q2 2010 | -6.5% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q1 2010 | -1.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro